Evidence map›Paper›PMID 34252354›Full record

ArticleBioengineered2021

MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.

Nan Lu, Jinhui Liu, Chengjian Ji, Yichun Wang, Zhipeng Wu, Shuning Yuan, Yan Xing, Feiyang Diao

Abstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nan LuDepartment of Reproduction, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jinhui LiuDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0001-8032-5099
Chengjian JiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yichun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhipeng WuDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Shuning YuanDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yan XingDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Feiyang DiaoDepartment of Reproduction, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterus Corpus Endometrial cancer (UCEC) is the sixth most common malignant tumor worldwide. In this research, we identified diagnostic and prognostic biomarkers to reflect patients' immune microenvironment and prognostic. Various data of UCEC patients from the TCGA database were obtained. Firstly, patients were divided into a high tumor mutation burden (TMB) level group and a low TMB level group according to the level of TMB. Then, differentially expressed miRNAs between the two groups were obtained. LASSO logistic regression analysis was used to construct a diagnostic model to predict the level of TMB. Univariate, multivariate, and LASSO regression analysis were used to construct a prognostic risk signature (PRS) to predict the prognosis of UCEC patients. Twenty-one miRNAs were used to construct a diagnostic model for predicting TMB levels. The AUC values of ROC curves for 21-miRNA-based diagnostic models were 0.911 in the training set, 0.827 in the test set, and 0.878 in the entire set. This diagnostic model showed positive correlation with TMB, PDL1 expression, and the infiltration of immune cells. In addition, three prognostic miRNAs were finally used to construct the PRS. The PRS was related to the expression of multiple immune checkpoints and the infiltration of multiple immune cells. Furthermore, the PRS can also reflect the response to some commonly used chemotherapy regimens. We have established a miRNA-based diagnostic model and a prognostic model that can predict the prognosis of UCEC patients and their response to chemotherapy and immunotherapy, thus providing valuable information on the choice of treatment regimen.

Indexed as

Endometrial NeoplasmsBiomarkers, TumorComputational BiologyDatabases, GeneticFemaleHumansImmunotherapyMicroRNAsMiddle AgedMutationPrognosisTranscriptomeBiomarkers, TumorMicroRNAsimmunotherapymiRNAsprognosis signatureTMBUCEC

Identifiers

PMID34252354
PMCPMC8806700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.